Navigation Links
Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
Date:11/29/2007

CAMBRIDGE, England, November 29 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology's 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.

AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role of each of these kinases in the development or progression of a variety of cancers. AT9283 is currently being investigated in three multi-centre clinical trials, including a Phase I/II study in patients with refractory haematological malignancies.

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs), currently in two multi-centre Phase 1 clinical trials.

AT9311 (also known as NVP-LCQ195) is also an inhibitor of CDKs, but with a pharmacological profile that is markedly different from that of AT7519. Astex is developing AT9311 in collaboration with Novartis.

Astex discovered all of these compounds using its proprietary fragment-based drug discovery platform Pyramid(TM).

"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases. Together with investigators from the M.D. Anderson Cancer Center and the UAB Comprehensive Cancer Center, we are reporting for the first time that one of these, AT9283, has already shown early signs of clinical efficacy as a single agent in the treatment of advanced refractory AML and CML," said Harren Jhoti, Chief Scientific Officer and Executive Vice President of Astex.

Hagop Kantarjian, Chairman of the Department of Leukemia at M.D. Anderson, Principal Investigator in the Phase I/II study of AT9283, said, "We see preliminary evidence of the anti-leukemic activity of AT9283 at well-tolerated doses in patients with relapsed and refra
'/>"/>

SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KGI Elects Three New Members to Board of Trustees
2. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
3. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
4. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
5. European Union has Three-Speed Healthcare System - Many Countries Lagging in Reform
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
10. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Eckert & Ziegler Vitalea Science ... services to the pharmaceutical and biotech industry, has announced ... in the position of Director of Science & Technology. ... valuable experience in drug metabolism and bioanalysis to EZVS ...
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... surgical procedures ... worldwide, ... medical device and tissue processing company,announced today that it has signed ... Adhesive into,a hernia repair kit. In addition to BioGlue, the kit ...
... 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... it reached a favourable,agreement with Johnson & ... outstanding patent litigation with respect to Conor,s,CoStar(R) ... in place, Angiotech expects that the resources,required ...
... WHAT: DENTAL IMPLANT MARKET INSIGHTS WEBINAR (audio ... presentation), WHEN: Wednesday, September ... Research Group, TO ENROLL: Please use the link below to register ... 416-364-7776 ext. 123 Millennium Research Group presents a ...
Cached Biology Technology:CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 2Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 4Dental Implant Market Insights Webinar 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... fertilizer technology used around the world today were developed ... and engineers at the Tennessee Valley Authority (TVA) in ... official. Shields is now Interim Director of IFDC, An ... in Muscle Shoals, Alabama. "An investment of ...
... patients churn out too much of a protein called ErbB2 ... to proliferate unchecked. Patients unlucky enough to be in ... prognoses and clinical outcomes than those who don,t. ... other chemotherapeutic agents, have improved this picture significantly, but leave ...
... ostentatious, sometimes bizarre qualities that improve a creature,s ... the reproductive separation of populations and the evolution ... biologists. In the September 2008 issue of ... Harald Parzer examine males from four geographically separated ...
Cached Biology News:TVA fertilizer technology used worldwide -- but few new products since 1970s 2TVA fertilizer technology used worldwide -- but few new products since 1970s 3TVA fertilizer technology used worldwide -- but few new products since 1970s 4CSHL scientists identify new drug target against virulent type of breast cancer 2CSHL scientists identify new drug target against virulent type of breast cancer 3How 'secondary' sex characters can drive the origin of species 2How 'secondary' sex characters can drive the origin of species 3